AstraZeneca Gets Verus’ Asthma Assets
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 89 (Table of Contents)
Published: 7 Nov-2007
DOI: 10.3833/pdr.v2007.i89.269 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
AstraZeneca has taken steps to relieve its current asthma woes by acquiring rights to a pediatric asthma development program from Verus Pharmaceuticals in a deal worth as much as US$310 M to Verus...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS